Abstract 466P
Background
Brain stem tumors are among the most severe oncological diseases in children. The only real method of help remains radiation therapy, which makes it possible to alleviate the severity of neurological disorders, but for most patients, the effect achieved, regardless of the type of ionizing radiation used, is temporary and after various periods (from 3 months to several years), the tumor resumes growth. The main purpose of our work was to determine the possibilities and prospects of repeated radiation therapy in children with diffuse brain stem tumors.
Methods
In the period 1998-2022, analysis of short and long-term results of 132 children and adolescents with brainstem tumors treated at the Russian Scientific Center of Roentgenoradiology were evaluated. Out of 132 patients treated at RNCRR, 60 children were selected whose remission lasted more than 9 months and the Lansky scale of more than 40 points for re-irradiation.
Results
As a result of re-irradiation, out of 45 children with a Lansky status of 40-50 points, it was improved in 36 (80%). An additional 15 children were included in the group with an initial Lansky status of 70-90 points, initially represented by one child, and only 9 patients' condition worsened or did not change. The median life expectancy in the group of patients after one course of radiation therapy was 13.9 months, but in the group of those treated repeatedly - 22.6 months.
Conclusions
Re-irradiation using 30.0 to 45.0 Gy in standard fractionation in combination with adequate accompanying therapy in 90% of cases allows an increase in the remission period in dense tumors and temporarily improve the quality of life in cystic solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
586P - Clinical and molecular characteristics of colorectal adenosquamous carcinoma: A multicenter retrospective study
Presenter: Jun Huang
Session: Poster session 16
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16